Clinical Trials Browser

Expanded_access × Rituximab × Other hematologic neoplasm × Clear all

NCT02136511 2014-10-28

Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia

Approved for marketing

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell